Mathematical modeling of (13)C label incorporation of the TCA cycle: the concept of composite precursor function by Uffmann, Kai & Gruetter, Rolf
Mathematical Modeling of 13C Label
Incorporation of the TCA Cycle:
The Concept of Composite Precursor Function
Kai Uffmann* and Rolf Gruetter
Laboratory of Functional and Metabolic Imaging, Ecole Polytechnique Fe´de´rale de Lausanne,
Lausanne, Switzerland
A novel approach for the mathematical modeling of 13C
label incorporation into amino acids via the TCA cycle
that eliminates the explicit calculation of the labeling of
the TCA cycle intermediates is described, resulting in
one differential equation per measurable time course of
labeled amino acid. The equations demonstrate that
both glutamate C4 and C3 labeling depend in a predicti-
ble manner on both transmitochondrial exchange rate,
VX, and TCA cycle rate, VTCA. For example, glutamate C4
labeling alone does not provide any information on either
VX or VTCA but rather a composite ‘‘ﬂux’’. Interestingly,
glutamate C3 simultaneously receives label not only from
pyruvate C3 but also from glutamate C4, described by
composite precursor functions that depend in a proba-
bilistic way on the ratio of VX to VTCA: An initial rate of
labeling of glutamate C3 (or C2) being close to zero is
indicative of a high VX/VTCA. The derived analytical solu-
tion of these equations shows that, when the labeling of
the precursor pool pyruvate reaches steady state quickly
compared with the turnover rate of the measured amino
acids, instantaneous labeling can be assumed for
pyruvate. The derived analytical solution has acceptable
errors compared with experimental uncertainty, thus
obviating precise knowledge on the labeling kinetics of
the precursor. In conclusion, a substantial reformulation
of the modeling of label ﬂow via the TCA cycle turnover
into the amino acids is presented in the current study.
This approach allows one to determine metabolic rates
by ﬁtting explicit mathematical functions to measured
time courses. VC 2007 Wiley-Liss, Inc.
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To gain insight into important cerebral metabolic
reactions, many modern methods have been established,
such as radiotracer methods, e.g., PET (Raichle et al.,
1975; Reivich et al., 1979), SPECT, and autoradiography
(Sokoloff et al., 1977), or methods based on stable iso-
topes, such as MR [17O (Ligeti et al., 1995), 13C (Beck-
mann et al., 1991)]. Typically, in all these approaches, the
rate of label incorporation into a product, P, from a single
precursor, S, is modeled by using a set of one or more or-
dinary differential equations (ODEs). The complexity of
the used network of ODEs depends on the speciﬁc reac-
tions and isotope ﬂuxes being studied (van den Berg and
Garﬁnkel, 1971; Cremer and Heath, 1974). Systems of up
to 200 coupled ODEs have been proposed for 13C NMR
studies (Chance et al., 1983) which allow the resolved
detection of multiple metabolites and resonance positions.
Efﬁcient and powerful software with a graphic user inter-
face (e.g., SAAM; The SAAM Institute, Seattle, WA) has
become available, with contemporary computing power
allowing us to extract metabolic ﬂuxes even from complex
multi-TCA cycle models. This classical approach has al-
ready uncovered very important features of label scram-
bling of glucose metabolism via the TCA cycle (Mason
et al., 1992; Gruetter et al., 2001).
However, not only a thorough understanding of the
involved biochemical processes but also knowledge of the
mathematics and good computer skills are required to
adapt the model for a speciﬁc problem and to implement
it in the chosen software. Thus, interpretation of the
underlying mathematical equations and the results
revealed by numerical solution are usually not intuitively
interpretable, as reviewed by Henry et al. (2006), and thus
are the subject of debate (Gruetter et al., 2001; Choi et al.,
2002; Mangia et al., 2003; Hyder et al., 2006).
As a result of the current experimental sensitivity
limitations, time courses of metabolite pools with low
concentrations such as TCA cycle intermediates are difﬁ-
cult, if not impossible, to determine. As a consequence,
the number of differential equations to be solved can be
higher than the number of measured time courses, which
is not a practical problem but obscures practical insight
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into existing relationships. For example, it has been well
established that calculating the labeling of glutamate C4
requires the solution of the labeling of oxoglutarate C4
(Mason et al., 1992). It is, however, not discussed in the
literature that glutamate C4 labeling can be described by a
single differential equation, with a simple mathematical
solution, as will be demonstrated. The present study
had three aims: First, to establish a mathematical for-
malism that requires solving only one differential equation
for each measurable time course of 13C label incorporation
into glutamate and aspartate via the TCA cycle intermedi-
ates; second, to combine all terms incorporating the
labeling from precursor pools into only one expression
representing a composite ‘‘driving function,’’ for which
the concept composite precursor functions (CPF) is intro-
duced; and, third, to establish analytical solutions for the
amino acid labeling, allowing determination of quantita-
tive criteria under which the precise measurement of the
rate of precursor labeling is obviated.
MATERIALS AND METHODS
Theory
The model is based on a previous model (Gruetter
et al., 2001) that includes the following steady-state assump-
tions: metabolite concentrations and ﬂuxes were considered to
be constant, and the concentration of TCA cycle intermedi-
ates is small compared with the concentrations of amino acids.
The current paper concerns the 13C label incorporation into
the amino acids via the TCA cycle intermediates, without
considering anaplerotic pathways or neuroglial compartmenta-
tion; i.e., only a single TCA cycle will be considered (Fig. 1).
With these assumptions, label incorporation into a car-
bon at position C of a product P can be written as eq. 1
(Gruetter et al., 1998), which is an ordinary differential equa-
tion (ODE):
d13PCðtÞ
dt
¼ VðinÞ 
13SðtÞ
½S|ﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄ}
influx
VðoutÞ 
13PCðtÞ
½P|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
efflux
¼ VðinÞ  PF
 VðoutÞ 
13PCðtÞ
½P : ð1Þ
This ODE describes the change of isotopic enrichment (IE) of
the carbon of the product P at position C, 13PC, resulting
from the difference of the sum of inﬂowing tracer from a sub-
strate S (ﬁrst term on the right side 5 inﬂux) and the label
ﬂowing out of the product pool (second term on the right
side 5 efﬂux). As the inﬂux includes the labeling of the pre-
cursor, this can be denoted by a precursor function (PF). [S]
and [P] represent the total concentration of the substrate pool
and the product pool, respectively.
Throughout this article, ‘‘isotopic enrichment (IE)’’ will
be used for the absolute concentration of enriched metabolite
13PC(t) in lmol  g–1, whereas ‘‘fractional enrichment (FE)’’
will stand for IE related to the total concentration of the
metabolite pool, i.e.,
13PCðtÞ
½P :
Thus the FE ranges from 0 to 1 and has no units.
At this point, two notational conventions are intro-
duced. First,
d13PCðtÞ
dt
;
the temporal derivative of the IE of 13PC(t) will be written as
dPC (lmol  g–1  min–1). Second, the symbol PC denotes the
dimensionless fractional enrichment (FE),
13PCðtÞ
½P :
The index C refers to the position of the labeled carbon.
As a result, eq. 1 is reformulated to
dPCðtÞ ¼ VðinÞ  S VðoutÞ  PC ¼ VðinÞ  PF VðoutÞ  PC:
ð2Þ
In general, however, the term V(in)  PF has to be adapted for
multiple ﬂuxes from several substrates. Accordingly, several
precursor pools deliver label at different rates (eq. 3). The
same applies to the efﬂuxes.
Fig. 1. The chemical pathways involved in the label incorporation
into amino acids via the TCA cycle included in the mathematical
model. Metabolites that can be measured by 13C MRS are printed in
boldface. The splitting of the arrows after label passed the pool of 2-
oxoglutarate (OG) represents the symmetry at the succinate level.
Glc, Lac, Pyr, OG, Glu, OAA, and Asp stand for glucose, lactate,
pyruvate, 2-oxoglutarate, glutamate, oxaloacetate, and aspartate,
respectively. The index at each metabolite name represents the posi-
tion of the carbon that gets labeled in that pool. The TCA cycle ﬂux
is represented by VTCA, whereas the transmitochondrial ﬂux is VX.
The indices denote the carbon position that becomes labeled accord-
ing to the pathways of the scheme after an injection of 1-13C
glucose.
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dPCðtÞ ¼
X
i
VðinÞi  Si 
X
j
VðoutÞj  PC ¼
X
i
VðinÞi
8>>:
9>>;CPF

X
j
VðoutÞj  PC with CPF ¼
P
i
VðinÞi  Si
P
i
VðinÞi
8>: 9>;: ð3Þ
In this notation, label input comes from multiple sources and
hence is termed composite precursor function (CPF). As will be
shown below, reformulation of analytical equations in terms
of composite precursor functions allows important insight into
isotope kinetics.
In this paper, three cases were examined: case 1 deals
with the label incorporation into Glu4, case 2 with incorpora-
tion into Glu4 and Glu2 or Glu3, and case 3 with incorpora-
tion into Glu4, Glu2, or Glu3 and Asp2 or Asp3.
Case 1. The equation to describe labeling incorpora-
tion into the carbon at position 4 of glutamate (PC 5 Glu4)
requires a second equation for the labeling of the carbon at posi-
tion 4 of oxoglutarate (PC 5 OG4). Replacing S and P in eq. 3
with the abbreviations of metabolites named oxoglutarate (P 5
OG) and glutamate (P 5 Glu), and considering the precursor
for these two pools, namely pyruvate labeled at carbon position
3 (Pyr3) and oxoglutarate labeled at carbon position 4 (OG4),
respectively, we will ﬁnd as in (Mason et al., 1992)
dGlu4 ¼ VX OG4  VX  Glu4
dOG4 ¼ VTCA  Pyr3 þ VX  Glu4  ðVX þ VTCAÞ OG4:
ð4Þ
Eliminating OG4 yields the following equation.
dGlu4 þ VXVX þ VTCA dOG4 ¼ Vgt  ðPyr3  Glu4Þ with
Vgt ¼ VXVTCAVX þ VTCA ð5Þ
Here the term Vgt was introduced with the same deﬁnition
as in Mason et al. (1992). When assuming that the temp-
oral change of the IE of pools with a much smaller concen-
tration can be neglected compared with pools with higher
concentrations
ðe:g: dOG4
dGlu4
<< 1Þ;
leads to the simpliﬁed ODE
dGlu4 ¼ Vgt  ðPyr3  Glu4Þ ¼ Vgt  PF Vgt  Glu4: ð6Þ
The PF introduced here is analogous to eq. 2 or 3, reﬂecting
the role of Pyr3 as the precursor of Glu4. The equation will
not differ when considering label ﬂow from [2-13C]acetyl-
CoA or [1-13C]Glc or [6-13C]Glc, provided that labeling
delays in glycolytic intermediates can be neglected.
Case 2. The symmetry of the succinate molecule implies
that the labeling time course of Glu2 and Glu3 can be represented
by the same equation (Yu et al., 1997), where Glu23 represents
label in Glu2 or Glu3, respectively. Using the same mathematical
assumption as for the derivation of eq. 6 the following expression
can be derived (for the derivation see Appendix)
dGlu23 ¼ VXVTCAð2VX þ VTCAÞðVX þ VTCAÞ  fðVX þ VTCAÞ
 Glu23 þ ðVX þ VTCAÞ  CPFg ð7Þ
with CPF 5 PX  Glu4 1 PTCA  Pyr3 and
PX ¼ VXVX þ VTCA and PTCA ¼
VTCA
VX þ VTCA :
It is of interest to note that, despite a single label pre-
cursor, Pyr3, Glu23 receives label input from two sources,
namely, Glu4 and Pyr3. For example, Glu23 will receive all
label input from Glu4 when VX/VTCA >> 1 (PX  1), and
increasingly Pyr3 will serve as label precursor with decreasing
VX/VTCA. Thus, the inﬂuence of both precursors can be
described by the composite precursor function CPF. To
emphasize the dependence of the labeling on Vgt and the ratio
x 5 VX/VTCA, eq. 7 can be rewritten as
dGlu23 ¼ Vgt xþ 1ð2xþ 1Þ  ðCPF Glu23Þ
¼ Vgt  f0ðxÞ  ðCPF Glu23Þ: ð8Þ
Case 3. The model was expanded to include the
labeling of aspartate at position 2 and 3, which will be
described with a single equation for Asp23 as was done for
Glu23 due to the symmetry of labeling at the succinate level.
Using a derivation as for cases 1 and 2 the set of ODEs
becomes (for derivation see Appendix)
dAsp23
dGlu23
8>: 9>;¼ fðVX;VTCAÞ ð2VXþVTCAÞ VX
VX ð2VXþVTCAÞ
8>: 9>;
Asp23
Glu23
8>: 9>;þðVXþVTCAÞ CPF
CPFASP
8>: 9>; ð9Þ
where
fðVX;VTCAÞ ¼ VXVTCA
2ðVX þ VTCAÞ2  V2TCA
and
CPF ¼ PX  Glu4 þ PTCA  Pyr3
CPFAsp ¼ PX  Asp23 þ PTCA  CPF:
ð10Þ
Eq. 6 holds for all cases in addition to the case-speciﬁc ODEs,
eq. 8 for case 2 and eq. 9 for case 3. Writing eq. 9 in a more
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compact form as a function of Vgt and x yields
dAsp23
dGlu23
8>: 9>; ¼ Vgt  f1ðxÞ f2ðxÞ
f2ðxÞ f1ðxÞ
8>: 9>; Asp23
Glu23
8>: 9>;
þf3ðxÞ
CPF
CPFASP
8>>: 9>>; ð11Þ
with
f 1ðxÞ ¼  ð2xþ 1Þðxþ 1Þ
2ðxþ 1Þ2  1 ; f2ðxÞ ¼
xðxþ 1Þ
2ðxþ 1Þ2  1 ;
f 3ðxÞ ¼ ðxþ 1Þ
2
2ðxþ 1Þ2  1 :
Finally, to estimate the impact of each term in eq. 8 and 11
on the labeling, it is very instructive to analyze the depend-
ence of Glu23 and Asp23 on x 5 VX/VTCA. For x between 1
and ?, which represent the complete range of reported x,
f0(x) ranges from 0.67 to 0.5, f1(x) from –0.83 to –1, f2(x)
from 0.29 to 0.5, and f3(x) from 0.57 to 0.5. In other words,
the functions fi(x) are only modestly dependent on x. Thus
the label incorporation into Glu23 and Asp23 is mainly de-
pendent on the CPF and Vgt, as will be shown in Results.
Analytical Solutions
In the following section, we show that for case 1 and
case 2 the ODEs for Glu4 (eq. 6) and Glu23 (eq. 8) can be
solved analytically. However, it is of advantage to assume an
analytical expression for the labeling of the precursor pyruvate
at position C3, Pyr3(t).
Due to the low concentration of pyruvate, it is not pos-
sible to measure the IE of pyruvate at position C3 directly
with 13C MRS. In general, measurements of the plasma glu-
cose or the IE of lactate at position C3 are considered to
deduce the IE of pyruvate (Gruetter et al., 1992; Mason et al.,
1992). To assess the effect of mildly delayed precursor enrich-
ment, it was assumed that the labeling of Pyr3 follows an ex-
ponential approach to steady state C:
Pyr3ðtÞ ¼ C  ½Pyr þ ðNA  ½Pyr  C  ½PyrÞ  ekt ¼ ½Pyr

n
Cþ ðNA CÞ  ekt
o
; ð12Þ
where NA is the natural abundance (NA 5 0.011) and C is
the fractional enrichment of pyruvate at steady state. The con-
stant k reﬂects the labeling rate of Pyr3.
The solution of ODEs as used in this model can be
found using the variation of constants method as shown in
part B of the Appendix. Additionally, the same method will
be used to derive the analytical expressions for the case in
which labeling of the precursor pyruvate reaches steady state
inﬁnitely fast, i.e., that Pyr3 is constant for all times, which
mathematically equals performing the transition k??.
Case 1. The ODE for the labeling of glutamate at
position 4 (eq. 6) in detailed notation to emphasize the time
dependence of respective terms is given by
dGlu4ðtÞ
dt
þ Vgt  Glu4ðtÞ½Glu ¼ Vgt 
Pyr3ðtÞ
½Pyr : ð13Þ
Utilizing the initial condition Glu4(t 5 0) 5 NA  [Glu], the
time course of Glu4 is given by
Glu4ðtÞ¼Vgt  Ckþ
NAC
k
ektðNACÞ k
kðkkÞe
kt
 
;
ð14Þ
with k 5 Vgt/[Glu]. When NA is negligible (NA/C << 1),
eq. 14 can be rewritten as
Glu4ðtÞ¼CVgtk  1e
ktþ k
kke
kt
 
¼C ½Glu 1ektþ k
kke
kt
 
: ð15Þ
Assuming that the labeling of the precursor Pyr3 reaches
steady state quickly compared with the turnover of Glu4 and
thus is constant for all times, and using the same method to
solve
dGlu4ðtÞ
dt
þ Vgt  Glu4ðtÞ½Glu ¼ Vgt 
Pyr3
½Pyr
with Pyr3 ¼ const: ¼ C  ½Pyr; ð16Þ
yields
Glu4ðtÞ ¼ C  ½Glu 

1 ekt

: ð17Þ
In other words, if it can be assumed that Pyr3 reaches steady-state
fast compared with Glu4 turnover, a step function can be assumed
for Pyr3 turnover and its explicit measurement is not necessary.
Case 2. The labeling of glutamate at position C3 (eq. 8)
will be solved in detailed notation explicitly representing the
time-dependent terms and is given by:
dGlu23ðtÞ
dt
¼ s  PX  Glu4ðtÞ½Glu þ PTCA 
Pyr3ðtÞ
½Pyr 
Glu23ðtÞ
½Glu
8>>: 9>>;
with s ¼ Vgt½Glu 
xþ 1
2xþ 1 ¼ k 
xþ 1
2xþ 1 ; ð18Þ
with the initial condition Glu23 5 NA  [Glu], the analytical
equation is given by
Glu23 ¼NA  ½Glu  est
þ s  ½Glu  PX k  Ck  s  ð1 e
stÞþ NACðk kÞðs kÞ
8>>:


ekt est

 ðNACÞ  k
kðk kÞðskÞ 

ekt est
9>>;
þ PTCA  Cs  ð1 e
stÞþNACðs kÞ 

ekt est
8>: 9>;;
ð19Þ
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with k and s as deﬁned in eq. 18. When assuming fast label-
ing of Pyr3 (k/k >> 1 and k/s >> 1) and NA/C << 1, this
equation will be simpliﬁed to
Glu23¼C  ½Glu  PX 

1 est

 s
sk 

ekt est
8: 9;n
þ PTCA 

1 est
o
: ð20Þ
In summary, we derived simpliﬁed analytical expressions that
describe the time course of Glu4 (eq. 17) and Glu23 (eq. 20),
assuming a constant labeling of Pyr3 for all times as well as a
negligible natural abundance.
Numerical Evaluation
Elimination of TCA Cycle Intermediates. To
investigate the impact of the simpliﬁcation of the set of ODE,
numerical solutions of the original complete set of ODE were
derived and compared with the results from simulating the
simpliﬁed new model. This comparison was carried out for
case 2 and case 3 and different values of VX 5 1, 2, 8 
VTCA, where VTCA 5 0.25 lmol/(g  min). The comparison
for case 2 was expanded by adding the time courses of Glu4
and Glu23 as calculated from the analytical expressions. The
pool concentrations for pyruvate, glutamate, aspartate, oxoglu-
trate, and oxaloacetate were assumed to be 0.1, 10, 3, 0.1,
and 0.1 lmol/g, respectively.
Assumption of a Constant Precursor Labeling. More-
over, to analyze the assumption of an immediate steady state of
the precursor labeling of pyruvate (k??), the residual between
the correct analytical solutions for Glu4 (eq. 14) and for Glu23
(eq. 19) with different labeling velocities of pyruvate, i.e., differ-
ent values of k (k5 0.1, 0.25, 0.5, 1, 2, 5, 10, 25, 50, 100 min–1),
and the analytical expressions simpliﬁed with k->? were calcu-
lated. As deﬁned in eq. 12, the range of k values represents possi-
ble labeling velocities, so that 95% steady-state FE of Pyr3 is
reached after 30, 12, 6, 3, 1.5, 0.6, 0.3, 0.2, 0.1, <0.1 min,
respectively. This analysis was performed with all integer values
ranging from 1 to 100 for a ratio of VX/VTCA using VTCA5 0.25
lmol/(g min).
RESULTS
Theory
By using the mathematical formulation of labeling
kinetics (eq. 1), it was found that eliminating all terms
related to the labeling of TCA cycle intermediates resulted
in one equation per observable metabolite. Assuming that
labeling of the precursor pyruvate is known, as a result the
solution of the simpliﬁed ODE is unambiguous.
Case 1. The labeling time course of Glu4 was
described by a single ODE, which was used in all three
cases and permits the derivation of a single ﬂux Vgt. Insofar
as this ODE depends only on Vgt and thus on both VX
and VTCA, it is explicitly obvious that no information can
be obtained on VTCA per se from the enrichment curve of
Glu4 without a priori knowledge of VX.
Case 2. In addition to eq. 6 for Glu4, the inclusion
of the isotopic enrichment of Glu23 requires one addi-
tional ODE. By using the concept of precursor functions,
both equations can be brought into a similar analytical
form separating the terms related to inﬂuxes from terms
concerning the efﬂuxes. The terms PX and PTCA in the
CPF (eq. 8) can be interpreted as probabilities that label
comes from the last previously labeled amino acid (here
Glu4) or is passed from the preceding chemical pathway
(i.e., from Pyr3) directly to Glu23. From this relation, it
became apparent that the route of label entering Glu23 was
determined by the ratio of VX/VTCA, because this ratio in
turn determines the probabilities PX and PTCA.
Case 3. Including Glu4, Glu23, and Asp23, a ma-
trix equation containing two terms was found to describe
labeling of Glu23 and Asp23 (eq. 11). The symmetric ma-
trix contains the ﬂuxes, which are the same for Asp23 and
Glu23, whereas the additional term with the CPFs contains
in addition to the common CPF an extra term for Glu23,
according to an input into Glu23 coming from Asp23.
Asp23 and Glu23 are coupled in this case, so they can be
treated as one system. Thus the matrix represents the efﬂu-
xes and the exchange of label between Glu23 and Asp23
across the TCA cycle, and the CPFs have to be interpreted
as the input to this system of coupled pools.
It can be seen that the CPFs attain an analogous ana-
lytical form as for case 2 (for Glu23); as follows: The pool
being labeled after Glu4 is Asp23, implying a CPF for
Asp23 similar to that of Glu23 in case 2, as was shown
eq. 7. Conversely, the CPF for Glu23 must incorporate
contributions from Asp23 as precursor. Thus, the precursor
ﬂuxes for Glu23 changed to CPFAsp as a combination of all
precursor ﬂuxes, where the factors PX and PTCA again
were interpreted as probabilities as in case 2 above. There-
fore, the probability that label enters into the pool of
Glu23 from the precursor Asp23 is PX, the probability
that it comes from Glu4 is determined by the product
PX  PTCA and the probability for Glu23 to receive label
from the pool Pyr3 is (PTCA)
2.
The evaluation of eq. 8 and 11 for x >> 1 reveals
that the numerical values of fi(x) do not vary strongly (see
Materials and Methods), whereas the CPF change their
complete shape, because Glu4 labels with a time constant
k–1 5 (Vgt/[Glu])
–1 when pyruvate is labeled fastest. With
increasing VX/VTCA, the probability that label is coming
directly from a preceding labeled amino acid is increas-
ingly dominating (PX approaching 1) such that Pyr3 loses
its functionality as an isotopic label precursor.
Numerical Evaluation
Elimination of TCA Cycle Intermediates. The
solutions of the exact and the simpliﬁed ODEs (Fig. 2)
show the typical evolution of 13C labeling time courses as
presented previously (Gruetter et al., 2001). In both cases
2 and 3, when increasing the ratio VX/VTCA Glu4
approaches steady state faster, and subsequent labeling of
Glu23 starts more slowly but later also increases more
strongly, thus describing an increasingly sigmoid curve. In
case 3, increasing VX/VTCA also emphasize the increasing
sigmoid shape of the FE of Asp23. In comparison with
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case 2, the sigmoid shape for the time course of Glu23
becomes slightly more intense in case 3 because of the fur-
ther delay caused by preceding labeling of Asp23.
For all three cases and any choice of parameters, the
time courses veriﬁed that the simpliﬁcation in the deriva-
tion of the present model yields a negligible deviation
from the enrichment curves calculated using the full set of
ODEs (Fig. 2). The deviation was maximally below
0.6%, which is far below the experimental error. Evalu-
ating the dependence of the error on the two cases, the
error of Glu23 increases when Asp23 was included, whereas
the error of Glu4 remained constant. The error was lower
with faster Pyr3 labeling, i.e., larger k (data not shown).
For Figure 2, k 5 4 min–1 was used to yield an estimation
of the upper bound of the error.
The upper row of graphs in Figure 2 also contains a
plot of the analytical solutions for Glu4 (eq. 14) and Glu23
(eq. 19; crosses). As expected, the solutions are identical to
those of the simpliﬁed ODEs.
Assumption of a Constant Precursor Label-
ing. When assuming that pyruvate labeling is rapid, i.e.,
k/k >> 1 and k/s >> 1, and comparing this with the so-
lution assuming a constant instantaneous Pyr3 labeling C
at t > 0, a small dependence on the ratio VX/VTCA was
observed (Fig. 3), which overall was negligible. As
expected, as k was increased, the deviations decreased
exponentially. The time course of Glu23 showed less devi-
ation for low values of k in comparison with Glu4 (Fig. 3).
Adapting the infusion protocol of the labeled glucose,
such that 95% of the steady-state concentration is reached
after 30 min, results in a deviation below 16% and 8% for
the FE of Glu4 and Glu23, respectively (Fig. 4). If such a
label concentration can be reached after only 12 min, this
already reduces the deviation to 8% and 3%, respectively.
These errors can be assumed to be negligible in relation to
experimental error.
DISCUSSION
The current paper describes a novel mathematical
framework for simplifying the mathematical modeling of
tracer incorporation, illustrated with the example of TCA
cycle rate determination by 13C NMR. We show that, if
changes in the labeling of TCA cycle intermediates can be
neglected compared with that in amino acids, the number
of differential equations required to describe the label
incorporation can be halved. Interestingly, the ﬂux rate
into Glu4 calculated thus is identical to the Vgt derived by
Mason et al. (1992), who used probability arguments.
Here we demonstrate that this derivation is valid only if
the rate of labeling of OG4 is negligible compared with
Fig. 2. The fractional enrichment of Glu4, Glu23, and Asp23 calcu-
lated with the set of ODEs describing the labeling pathway either
including the TCA cycle intermediates (exact 5 sold lines) or with-
out them (simple 5 dots) and calculated from the analytical solutions
of the simpliﬁed ODE (analyt. 5 crosses). This calculation was per-
formed for different ratios of VX/VTCA 5 1, 2, 8 (columns from left
to right). The FEs in the upper row of graphs are derived from the
model neglecting the labeling of oxaloacetate and aspartate but
include the analytical solutions (case 2), whereas the lower row shows
FEs resulting from the model including labeling of aspartate (case 3).
With increasing VX, the sigmoid character of the time courses
becomes more intense.
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that of Glu4, which is a condition that has not been estab-
lished to date.
Speciﬁcally, the presented model yielded a simpliﬁed
set of a reduced number of ODEs describing the label
incorporation into the amino acids resulting from meta-
bolic reactions ascribed to the TCA cycle. The labeling of
glutamate at positions C2, C3, C4, and of aspartate at
positions C2, C3 can be described with only ﬁve ODEs,
namely, eq. 6 and 9.
Label ﬂows into Asp23 from either Pyr3 or Glu4 and
similarly for Glu23, and this ﬂow can be described by com-
posite precursor functions. We are not aware of any
description of the labeling of Asp23 and Glu23 in such a
manner. When interpreting the driving input functions of
the ODEs (composite precursor function) as terms repre-
senting the probability that label comes from the directly
previously labeled amino acid or from preceding labeled
pools, for example, for a very high VX/VTCA, the label is
mostly received from the latest labeled amino acid pool
instead of any other pool labeled earlier in the metabolic
pathway.
From eq. 6, it is clear that, with a step function in
Pyr3, Glu4 will follow an exponential time course (1 – e
–kt)
with k 5 Vgt/Glu, which is conﬁrmed by the analytical
expression for Glu4 (eq. 17). As has been shown previ-
ously (Choi and Gruetter, 2004), with such a signiﬁcant
delay, when Glu4 is the precursor, (VX/VTCA >> 1) will
lead to a sigmoidal shape of the label curve for Glu23. For
example, from eq. 20, VX/VTCA >> 1 implies PX  1
and PTCA  0 and hence Glu23/[Glu] 5 C(1 – 2e–st 1
e–kt) 5 C(1 – e–st)2. Clearly, the ﬁrst derivative of this
function with time is initially zero; hence, with VX/VTCA
>> 1, it is shown analytically that Glu23 labeling at t 5 0
should be very slow. The approximations for this deriva-
tion require fast precursor labeling for Glu23 (k/k >> 1)
and a high enrichment (NA/C << 1), so they can be eas-
ily veriﬁed from experimental data fulﬁlling these condi-
tions. As expected from eq. 8 or analytically from eq. 20,
it was found that the sigmoid nature of the labeling curves
increases with VX. If VX is higher, more label enters into
the amino acids and thus arrives later in the next pool of
amino acids on the pathway. This delay causes a less steep
slope at the beginning of the labeling time course of later-
labeled amino acids and thus a more curved sigmoid,
implying that the CPF is dominated by the direct precur-
sor, e.g., Glu4 for Asp23, Asp23 for Glu23, or Glu4 for
Glu23, if Asp23 is not included. Hence, with the formula-
Fig. 3. The two graphs show the maximal residual value of the FE of Glu4 (left) and Glu3 (right)
if calculated with the assumption that the precursor pyruvate labels inﬁnitely fast instead of using
the exact equation depending on the ratio VX/VTCA and the velocity of pyruvate labeling, repre-
sented by k. Even for very low k, the residual will not exceed 16% for Glu4 and 8% for Glu3.
There is no remarkable dependence on the ratio VX/VTCA.
Fig. 4. Similar to Figure 3, the graph shows the residual of the exact
FE of Glu4 and Glu3 and these FEs calculated assuming that the py-
ruvate labeling is inﬁnitely fast. The residual is plotted vs. the velocity
constant of pyruvate labeling k, assigned to the abscissa at the top.
The time displayed on the bottom abscissa corresponds to the time at
which pyruvate reached 95% of the steady-state labeling. When using
the simpliﬁcation of an inﬁnitely fast precursor labeling, this graph
shows which deviation has to be taken into account for a given infu-
sion protocol, represented by value k or the time until 95% labeling
is achieved. Conversely, this graph can be used to adapt the infusion
protocol to minimize the deviation.
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tion of the CPFs, the sensitivity of the labeling time
courses to VX/VTCA can be evaluated. The increasing sig-
moidal shape further implies that the ratio of VX/VTCA is
best determined at the initial points of the labeling time
courses and not in the data acquired at steady state.
This interpretation of the ODEs as presented above
conﬁrms former ﬁndings based on an analysis of experi-
mental data with the help of mathematical modeling
(Mason et al., 1992). Thus this interpretation of the math-
ematical expressions reﬂects only the intuitive character of
the concept of CPFs. Furthermore, eq. 6 explicitly states
that it is not possible to determine either the TCA cycle
ﬂux VTCA or the mitochondrial ﬂux VX from measuring
the labeling time course of glutamate in position C4.
Instead, from the deﬁnition of Vgt (eq. 6), it is apparent
that Vgt is always smaller than VTCA. Thus, assuming that
Vgt 5 VTCA (VX >> VTCA) leads to an underestimation
of VTCA and consequently of the total glucose consump-
tion (CMRglc) rate of the brain. In this context, it is of in-
terest to note that some previously published values of
VTCA, ranging from 0.47 to 0.53 lmol/g, obtained
with the assumption that VX >> VTCA (Hyder et al.,
1996, 1997; Sibson et al., 1998; Patel et al., 2004), are
lower than results found with 13C NMR (Henry et al.,
2002) as well as with other tracer methods, such as 17O
NMR (Zhu et al., 2002) or autoradiography (Nakao
et al., 2001), which ranged from 0.71 to 0.83 lmol/g
under similar anesthesia conditions (a-chloralose).
Analytical solutions of the ODEs could also be
derived. However, not using any further simpliﬁcation,
unlike the resulting expressions for Glu4 (eq. 14), which is
fairly simple, the function Glu23 (eq. 19) already has a
fairly complex structure, which is difﬁcult to interpret.
Solving the coupled ODEs of Glu23 and Asp23 yields
terms that are beyond the scope of this manuscript and
will be presented elsewhere.
However, the fact that now one analytical solution is
available for either ﬁtting the time course of Glu4 to deter-
mine Vgt or Glu3 to determine the ratio VX/VTCA reveals
a unique tool for analyzing the data of a 1-13C-glucose
MRS experiment. Consequently, measuring both labeling
curves allows for derivation of both ﬂuxes, VX and VTCA.
Moreover, the model presented shows that a precise
knowledge of the precursor labeling of pyruvate is no
longer required, as long as the infusion protocol guaran-
tees a sufﬁciently fast labeling compared with the amino
acid label turnover rates. Even a less perfectly adapted
infusion protocol that reaches a steady state of pyruvate
labeling after about 30 min results in negligibly low devi-
ations from the correct expression of the time courses of
Glu4 and Glu23 when related to experimental accuracy.
Henry et al. (2002) established an infusion protocol of la-
beled glucose that fulﬁlls this criterion. With this addi-
tional simpliﬁcation, Pyr3 5 const, the analytical expres-
sions of Glu4 and Glu23 fall into a straightforward form
such that the ﬁtting process can be done with even com-
mon software, such as Excel or Origin. With this step, a
signiﬁcant practical problem of in vivo 13C MRS studies
is solved.
CONCLUSIONS
We conclude that the explicit solution of the label-
ing of the TCA cycle intermediates can be eliminated
from the mathematical model, resulting in a reduced num-
ber of necessary ODEs to one equation per measurable
metabolite pool. Formulation of the composite precursor
functions showed that measuring time points at the begin-
ning of the labeling yields valuable information for the
determination of VX. The model thus offers a formal
method to investigate the principles of label kinetics in
such 13C turnover experiments leading to analytical
expressions. We further conclude that, provided that the
precursor, e.g., Pyr, approaches steady-state quickly com-
pared with the rate of labeling of the amino acid investi-
gated, the analytical solution assuming instantaneous label-
ing can be used.
REFERENCES
Beckmann N, Turkalj I, Seelig J, Keller U. 1991. 13C NMR for the
assessment of human brain glucose metabolism in vivo. Biochemistry
30:6362–6366.
Chance EM, Seeholzer SH, Kobayashi K, Williamson JR. 1983. Mathe-
matical analysis of isotope labeling in the citric acid cycle with applica-
tions to 13C NMR studies in perfused rat hearts. J Biol Chem
258:13785–13794.
Choi IY, Gruetter R. 2004. Dynamic or inert metabolism? Turnover of
N-acetyl aspartate and glutathione from D-[1-13C]glucose in the rat
brain in vivo. J Neurochem 91:778–787.
Choi IY, Lei H, Gruetter R. 2002. Effect of deep pentobarbital anesthe-
sia on neurotransmitter metabolism in vivo: on the correlation of total
glucose consumption with glutamatergic action. J Cereb Blood Flow
Metab 22:1343–1351.
Cremer JE, Heath DF. 1974. The estimation of rates of utilization of glu-
cose and ketone bodies in the brain of the suckling rat using compart-
mental analysis of isotopic data. Biochem J 142:527–544.
Gruetter R, Novotny EJ, Boulware SD, Rothman DL, Mason GF, Shul-
man GI, Shulman RG, Tamborlane WV. 1992. Direct measurement of
brain glucose concentrations in humans by 13C NMR spectroscopy.
Proc Natl Acad Sci U S A 89:1109–1112.
Gruetter R, Seaquist ER, Kim S, Ugurbil K. 1998. Localized in vivo
13C-NMR of glutamate metabolism in the human brain: initial results
at 4 Tesla. Dev Neurosci 20:380–388.
Gruetter R, Seaquist ER, Ugurbil K. 2001. A mathematical model of
compartmentalized neurotransmitter metabolism in the human brain.
Am J Physiol Endocrinol Metab 281:E100–E112.
Henry PG, Lebon V, Vaufrey F, Brouillet E, Hantraye P, Bloch G.
2002. Decreased TCA cycle rate in the rat brain after acute 3-NP treat-
ment measured by in vivo 1H-[13C] NMR spectroscopy. J Neurochem
82:857–866.
Henry PG, Adriany G, Deelchand D, Gruetter R, Marjanska M, Oz G,
Seaquist ER, Shestov A, Ugurbil K. 2006. In vivo 13C NMR spectros-
copy and metabolic modeling in the brain: a practical perspective. Mag-
net Reson Imag 24:527–539.
Hyder F, Chase JR, Behar KL, Mason GF, Siddeek M, Rothman DL,
Shulman RG. 1996. Increased tricarboxylic acid cycle ﬂux in rat brain
during forepaw stimulation detected with 1H[13C]NMR. Proc Natl
Acad Sci U S A 93:7612–7617.
Hyder F, Rothman DL, Mason GF, Rangarajan A, Behar KL, Shulman
RG. 1997. Oxidative glucose metabolism in rat brain during single
forepaw stimulation: a spatially localized 1H[13C] nuclear magnetic reso-
nance study. J Cereb Blood Flow Metab 17:1040–1047.
Modeling of 13C Label Incorporation Via TCA Cycle 3311
Journal of Neuroscience Research DOI 10.1002/jnr
Hyder F, Patel AB, Gjedde A, Rothman DL, Behar KL, Shulman RG.
2006. Neuronal–glial glucose oxidation and glutamatergic-GABAergic
function. J Cereb Blood Flow Metab 26:865–877.
Ligeti L, Pekar J, Ruttner Z, McLaughlin AC. 1995. Determination of
cerebral oxygen consumption and blood ﬂow by magnetic resonance
imaging. Acta Biomed Ateneo Parmense 66:67–74.
Mangia S, Giove F, Bianciardi M, Di Salle F, Garreffa G, Maraviglia B.
2003. Issues concerning the construction of a metabolic model for neu-
ronal activation. J Neurosci Res 71:463–467.
Mason GF, Rothman DL, Behar KL, Shulman RG. 1992. NMR
determination of the TCA cycle rate and alpha-ketoglutarate/gluta-
mate exchange rate in rat brain. J Cereb Blood Flow Metab 12:434–
447.
Nakao Y, Itoh Y, Kuang TY, Cook M, Jehle J, Sokoloff L. 2001. Effects
of anesthesia on functional activation of cerebral blood ﬂow and metab-
olism. Proc Natl Acad Sci U S A 98:7593–7598.
Patel AB, de Graaf RA, Mason GF, Kanamatsu T, Rothman DL, Shul-
man RG, Behar KL. 2004. Glutamatergic neurotransmission and neuro-
nal glucose oxidation are coupled during intense neuronal activation.
J Cereb Blood Flow Metab 24:972–985.
Raichle ME, Larson KB, Phelps ME, Grubb RL Jr, Welch MJ, Ter-
Pogossian MM. 1975. In vivo measurement of brain glucose transport
and metabolism employing glucose-11C. Am J Physiol 228:1936–1948.
Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, Casella V,
Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L. 1979. The [18F]ﬂu-
orodeoxyglucose method for the measurement of local cerebral glucose
utilization in man. Circ Res 44:127–137.
Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman
RG. 1998. Stoichiometric coupling of brain glucose metabolism and
glutamatergic neuronal activity. Proc Natl Acad Sci U S A 95:316–321.
Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Petti-
grew KD, Sakurada O, Shinohara M. 1977. The [14C]deoxyglucose
method for the measurement of local cerebral glucose utilization:
theory, procedure, and normal values in the conscious and anesthetized
albino rat. J Neurochem 28:897–916.
van den Berg CJ, Garﬁnkel D. 1971. A stimulation study of brain com-
partments. Metabolism of glutamate and related substances in mouse
brain. Biochem J 123:211–218.
Yu X, Alpert NM, Lewandowski ED. 1997. Modeling enrichment
kinetics from dynamic 13C-NMR spectra: theoretical analysis and prac-
tical considerations. Am J Physiol 272:C2037–C2048.
Zhu XH, Zhang Y, Tian RX, Lei H, Zhang N, Zhang X, Merkle H,
Ugurbil K, Chen W. 2002. Development of 17O NMR approach for
fast imaging of cerebral metabolic rate of oxygen in rat brain at high
ﬁeld. Proc Natl Acad Sci U S A 99:13194–13199.
APPENDIX
Derivation of the Simpliﬁed ODE
With the use of eq. 1, the following set of 10 ODEs
(eq. A1) describes the label kinetics related to the chemical
pathways represented schematically in Figure 1. Commas in
the index refer to differential equations of the same form but
describing label incorporation at different carbon positions.
dGlu2;3;4 ¼ VX OG2;3;4  VX  Glu2;3;4 ) OG2;3;4 ¼ 1VX dGlu2;3;4 þ Glu2;3;4
dAsp2;3 ¼ VX OAA2;3  VX  Asp2;3 ) OAA2;3 ¼
1
VX
dAsp2;3 þ Asp2;3
dOG2;3 ¼ VTCA OAA2;3 þ VX  Glu2;3  ðVX þ VTCAÞ OG2;3
dOG4 ¼ VTCA  Pyr3 þ VX  Glu4  ðVX þ VTCAÞ OG4
dOAA2;3 ¼ VTCA
2
OG3 þ VTCA
2
OG4 þ VX  Asp2;3  ðVX þ VTCAÞ OAA2;3:
ðA1Þ
Due to the symmetry of succinate, labeling of gluta-
mate and aspartate at carbon position 2 and 3 can be
described by the same equation in our model (Yu
et al., 1997), which will be denoted below by the
index ‘‘23.’’
Case 2. To ﬁlter out the information hidden in
the labeling time courses of Glu4 and Glu23 only, we will
ignore the labeling incorporation into the pools of aspar-
tate, i.e., oxaloacetate, for the time being. Thus, the set of
equations (eq. A1) reduces to
dGlu23;4 ¼ VX OG23;4  VX  Glu23;4 ) OG23;4 ¼ 1VX dGlu23;4 þ Glu23;4
dOG23 ¼ VTCA
2
OG23 þ VTCA
2
OG4 þ VX  Glu23  ðVX þ VTCAÞ OG23
dOG4 ¼ VTCA  Pyr3 þ VX  Glu4  ðVX þ VTCAÞ OG4
ðA2Þ
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Aiming for elimination of the expressions for the
TCA cycle intermediates, we replace the terms of OAA
and OG in the last two equations with the expressions
from the ﬁrst equation. This gives eq. 5 and eq. A3.
dGlu4þ VXVXþVTCA dOG4¼
VX VTCA
VXþVTCA  ðPyr3Glu4Þ
ð5Þ
dGlu23þ 2VX
2VXþVTCA dOG23þ
VXVTCA
ð2VXþVTCAÞðVXþVTCAÞ dOG4¼
VXVTCA
ð2VXþVTCAÞðVXþVTCAÞ fðVXþVTCAÞ Glu23þVX Glu4þVTCA Pyr3g:
ðA3Þ
In view of the fact that the concentration of the TCA
intermediates is much lower than the pool size of the
amino acids, the enrichment of the OAA2,3 reaches steady
state much faster than Asp2,3. Because the labeling follows
an exponential evolution in reaching a steady state,
dOAA2,3 approaches zero, whereas the labeling velocity
of Asp2,3 (dAsp2,3) is still of signiﬁcant amplitude. This
applies in the same way for OG2,3,4 and Glu2,3,4, respec-
tively. Additionally,
VX
VXþVTCA<1
holds, because VX and VTCA are always positive. Hence
the second terms on the left side of eq. 5 and eq. A3 can
be omitted, resulting in eq. 6 and eq. 7, respectively.
dGlu4¼Vgt  ðGlu4þPyr3ÞwithVgt¼
VXVTCA
VXþVTCA :
ð6Þ
dGlu23¼ VXVTCAð2VXþVTCAÞðVXþVTCAÞ fðVXþVTCAÞ
Glu23þVX Glu4þVTCA Pyr3g
i.e.,
dGlu23¼ VXVTCAð2VXþVTCAÞðVXþVTCAÞ fðVXþVTCAÞ
Glu23þðVXþVTCAÞ CPFg ð7Þ
with CPF5 PX  Glu41 PTCA  Pyr3 and
PX ¼ VXVX þ VTCA and PTCA ¼
VTCA
VX þ VTCA :
At this point, it is very instructive to introduce the
concept of the composite precursor ﬂuxes (CPF), which
are the driving input functions for the differential equa-
tions. Substituting the factors
VX
VX þ VTCA and
VTCA
VX þ VTCA
with PX and PTCA, respectively, we can deﬁne an adapted
CPF for Glu23. This is possible for each labeled amino
acid, as shown below.
Case 3. Processing the complete set of ODE,
including aspartate and oxaloacetate, according to the steps
described above, we will ﬁnd
dGlu23 þ VXVX þ VTCA  dOG23 
VTCA
VX þ VTCA  dAsp23
¼ VX  VTCA
VX þ VTCA  ðAsp23  Glu23Þ ðA4Þ
dGlu4þ VXVXþVTCA dOG4¼
VX VTCA
VXþVTCA  ðPyr3Glu4Þ
ðA5Þ
dAsp23þ
VX
VXþVTCA dOAA23
VTCA
2  ðVXþVTCAÞ
 ðdGlu3þdGlu4Þ¼ VX VTCAVXþVTCA
 1
2
Glu3þ1
2
Glu4Asp23
8>: 9>;: ðA6Þ
By using the same arguments as above, the terms related
to the TCA cycle intermediates can again be eliminated.
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dGlu23 VTCAVXþVTCA dAsp23 ¼
VX VTCA
VXþVTCA  ðAsp23Glu23Þ
dGlu4¼ VX VTCAVXþVTCA  ðPyr3Glu4Þ
dAsp23
VTCA
2  ðVXþVTCAÞ  ðdGlu23þdGlu4Þ¼
VX VTCA
VXþVTCA 
1
2
Glu23þ1
2
Glu4Asp23
8>: 9>;:
ðA7Þ
Further on, this set of ODEs can be rephrased to give sep-
arate equations for each labeled carbon position of all
involved amino acids (eq. A8).
dGlu4 ¼Vgt fGlu4þPyr3g with Vgt¼ VXVTCAVXþVTCA
dAsp23¼ fðVX=VTCAÞ fð2VXþVTCAÞ Asp3þVX  ðGlu23þGlu4ÞþVTCA Pyr3g
dGlu23¼ fðVX=VTCAÞ  2VX Asp3ð2VXþVTCAÞ Glu23þ
VTCA
VXþVTCA  ðVX Glu4þVTCA Pyr3Þ
 
:
ðA8Þ
The function
f VX

VTCA
8: 9;¼ VXVTCA
2ðVXþVTCAÞ2V2TCA
¼ x
2ðxþ1Þ21 with x¼VX

VTCA
in eq. A8 is dimensionless.
Applying the concept of composite precursor func-
tions again leads to a comprehensive form of the set of
ODEs (eq. A8) for labeling of aspartate and glutamate at
carbon positions 2 and 3.
dAsp23
dGlu23
8>: 9>;¼ fðVX;VTCAÞ  ð2VX þ VTCAÞ VXVX ð2VX þ VTCAÞ
8>: 9>; Asp23
Glu23
8>: 9>;þ ðVX þ VTCAÞ CPFCPFASP
8>: 9>; 
ð9Þ
with f as above and
CPF¼PX Glu4þPTCA Pyr3
CPFAsp¼PX Asp23þPTCA CPF:
ð10Þ
Also in this case, labeling of glutamate at carbon position 4
still follows
dGlu4¼Vgt fGlu4þPyr3g with Vgt¼
VXVTCA
VXþVTCA :
ð6Þ
Analytical Solutions of the Simpliﬁed ODE
In the following, according to case 1 and case 2, the
ODEs for Glu4 and Glu23 will be solved analytically.
Case 1. The ODE for the labeling of glutamate at
position 4 is
dGlu4 ¼ Vgt  ðPyr3  Glu4Þ ¼ Vgt  PF Vgt  Glu4
with Vgt ¼ VXVTCAVX þ VTCA : ð6Þ
For the following calculation, we will again use the more
detailed notation to emphasize the time dependence of
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the terms in eq. 6:
dGlu4ðtÞ
dt
þ Vgt  Glu4ðtÞ½Glu ¼ Vgt 
Pyr3ðtÞ
½Pyr : ð13Þ
Labeling of Pyr3 is assumed to follow
Pyr3ðtÞ ¼ C  ½Pyr þ ðNA  ½Pyr  C  ½PyrÞ  ekt
¼ ½Pyr  fCþ ðNA CÞ  ektg; ð12Þ
where NA is the natural abundance (NA 5 0.011) and C is
the fraction of the concentration of labeled molecules reached
at steady state. The constant k reﬂects the labeling velocity
of Pyr3. Since this time course is not constant and nonzero,
eq. 13 is a nonhomogeneous ODE of the ﬁrst order.
The solution of such an ODE consists of the addi-
tion of a solution, yH, of the homogeneous equation
dGlu4
dt
þ k  Glu4 ¼ 0 with k ¼ Vgt½Glu ðB1Þ
and one speciﬁc solution of the inhomogeneous ODE,
yS. With the usual ansatz, the latter equation yields
yH 5 c  e–kt.
Using the variation of constants method with the
ansatz yS 5 c(t)  e–kt the product rule yields y0S 5 c0(t) 
e–kt – c(t)  k  e–kt, where the apostrophe designates the
temporal derivative. Inserting this and the expression for
Pyr3 (eq. 12) into the nonhomogeneous ODE (eq. 13)
gives
c0ðtÞ  ekt  cðtÞ  k  ekt þ k  cðtÞ  ekt
¼ Vgt  fCþ ðNA CÞ  ektg: ðB2Þ
Integration of the resulting equation
c0ðtÞ ¼ Vgt  fC  ekt þ ðNA CÞ  eðkkÞtg; ðB3Þ
yields
cðtÞ ¼ Vgt  Ck þ
NA C
k k  e
kt
 
 ekt: ðB4Þ
Thus one speciﬁc solution of the ODE (eq. 13) is
yS ¼ Vgt  Ck þ
NA C
k k  e
kt
 
: ðB5Þ
In this manner, an explicit function describing the
time course of Glu4 was found:
Glu4ðtÞ¼ySþyH¼Vgt  Ckþ
NAC
kk e
kt
 
þc ekt:
ðB6Þ
Finally, the integration constant c remains to be
determined by using the initial condition Glu4(t 5 0) 5
NA  [Glu]. With
Glu4ð0Þ ¼ Vgt  Ck þ
NA C
k k
 
þ c ¼ NA  ½Glu;
ðB7Þ
we ﬁnd
Glu4ðtÞ ¼ Vgt  Ck þ
NA C
k k  e
kt  ðNA CÞ

 k
k  ðk kÞ  e
kt

: ð14Þ
Assuming that the time course of the precursor Pyr3 is
constant, i.e., is a step function, and using the same
method to solve the following equation
dGlu4ðtÞ
dt
 Vgt  Glu4ðtÞ½Glu ¼ Vgt 
Pyr3
½Pyr with
Pyr3 ¼ const: ¼ C  ½Pyr ð16Þ
yields
Glu4ðtÞ ¼ ½Glu  fCþ ðNA CÞ  ektg: ðB8Þ
This equals the assumption that Pyr3 reaches steady state
inﬁnitely fast; i.e., k is inﬁnitely high. Thus analyzing
eq. 14 in the limit k?? and replacing
k ¼ Vgt
½Glu
leads to the same expression (eq. B8).
Furthermore, we can assume that the natural
abundance, NA, is very small compared with the steady
concentration C and set NA 5 0. This yields a very
compact form for the function describing the labeling
of Glu4:
Glu4ðtÞ ¼ C  ½Glu  ð1 ektÞ: ð17Þ
Case 2. By analogy to the derivation above, it is
also possible to solve equation eq. 8:
dGlu23 ¼ Vgt xþ 1ð2xþ 1Þ  ðCPF Glu23Þ
¼ Vgt  f0ðxÞ  ðCPF Glu23Þ; ð8Þ
where x5VX/VTCA andCPF ¼ PX  Glu4 þ PTCA  Pyr3:
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The respective nonhomogeneous equation with the com-
mon extended notation reads as follows:
dGlu23ðtÞ
dt
¼ s  ½Glu  PX Glu4ðtÞ½Glu þPTCA
8>: Pyr3ðtÞ½Pyr Glu23ðtÞ½Glu
9>;
with s¼ Vgt½Glu 
xþ 1
2xþ 1¼ k 
xþ 1
2xþ 1 ; ð18Þ
i.e.,
dGlu23
dt
þ s Glu23 ¼ s  ½Glu  PX  Glu4½Glu þPTCA 
Pyr3
½Pyr
8>: 9>;
or
dGlu23
dt
þ s Glu23 ¼ s  ½Glu 
(
PX k
C
k
þNAC
k k  e
ktðNACÞ  k
kðk kÞ  e
kt
8>: 9>;
þPTCA  ðCþðNACÞ  ektÞ
)
: ðB9Þ
Solving the homogeneous equation
dGlu23
dt
þ s  Glu23 ¼ 0
yields yH 5 c  e–st.
As above, using the ansatz yS 5 c(t)  e–st and y0S 5
c0(t)  e–st – c(t)  s  e–st for the speciﬁc solution, we have
to integrate
c0ðtÞ¼ s  ½Glu 
n
PX k
C
k
estþNAC
kk e
ðskÞtðNACÞ  k
kðkkÞ e
ðskÞt
8>: 9>;
þPTCA  C estþðNACÞ eðskÞt
 o
; ðB10Þ
which results in
cðtÞ¼ s  ½Glu 
(
PX k  Ck s e
stþ NACðkkÞðskÞ
8>:
 eðskÞtðNACÞ  k
kðkkÞðskÞ e
ðskÞt
9>;
þPTCA  Cs e
stþNACðskÞ e
ðskÞt
8>: 9>;
)
ðB11Þ
and ﬁnally yields
yS¼cðtÞest¼s½Glu PX k Cksþ
NAC
ðkkÞðskÞe
kt
8>:
ðNACÞ k
kðkkÞðskÞe
kt
9>;
þPTCA  Csþ
NAC
ðskÞ e
kt
8>: 9>;: ðB12Þ
Thus, the complete solution is
Glu23 ¼ yS þ yH ¼ c  est þ s  ½Glu
 PX  k  Ck  sþ
NA C
ðk kÞðs kÞ  e
kt
8>:
ðNA CÞ  k
kðk kÞðs kÞ  e
kt
9>;
þPTCA  Cs þ
NA C
ðs kÞ  e
kt
8>: 9>;: ðB13Þ
To determine the constant of integration, we use the
initial condition Glu23 (0) 5 NA  [Glu] and ﬁnd
c ¼ NA  ½Glu  s  ½Glu
 PX  k  Ck  sþ
NA C
ðk kÞðs kÞ
8>: 9>; ðNA CÞ
 k
kðk kÞðs kÞ
9>;þ PTCA  Cs þNA Cðs kÞ
8>: 9>;:
ðB14Þ
Inserting this result into the equation above, the
time course of Glu23 follows
Glu23¼NA  ½Glu ests  ½Glu  PX k  Ck s e
stþ NACðkkÞðskÞe
stðNACÞ k
kðkkÞðskÞe
st
8>: 9>;
þ PTCA  Cs þ
NAC
ðskÞ
8>: 9>; estþs  ½Glu  PX k  Ck sþ NACðkkÞðskÞektðNACÞ kkðkkÞðskÞekt
8>: 9>;
þ PTCA  Cs þ
NAC
ðskÞ e
kt
8>: 9>; ðB15Þ
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Glu23¼NA  ½Glu estþs  ½Glu  PX k  Ck s 

1est

þ NACðkkÞðskÞ 

ektest

 ðNACÞ k
kðkkÞðskÞ
8>:


ektest

þPTCA  Cs 

1est

þNACðskÞ 

ektest
8>: 9>;9>; : ð19Þ
As before, we want to analyze the assumption of a
constant precursor function, i.e., k?? and ﬁnd
Glu23¼NA  ½Glu estþs  ½Glu  PX k  Ck s  ð1e
stÞðNACÞ
kðskÞ  ðe
ktestÞ
8>: 9>;þPTCA  Cs  ð1estÞ
8>: 9>; 
¼NA  ½Glu estþs  ½Glu  PX  Cs  ð1e
stÞðNACÞ
sk  ðe
ktestÞ
8>: 9>;þPTCA  Cs  ð1estÞ
8>: 9>; ;
ðB16Þ
which is exactly what would be found if the nonhomoge-
neous differential equation would be solved with the
assumption the Pyr35 C  [Pyr]5 const.
Under the assumption, again, that NA is negligible
compared with C, it can be eliminated from the equation
above, which results in
Glu23¼C  ½Glu  PX  ð1estÞ ssk  ðe
ktestÞ
8: 9;n
þPTCA  ð1estÞ
o
: ð20Þ
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